New York City, NY -- (SBWIRE) -- 01/10/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Galectin Therapeutics Inc. (NASDAQ:GALT), Conatus Pharmaceuticals Inc (NASDAQ:CNAT), Marina Biotech, Inc. (OTCMKTS:MRNA)
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) gained 281.09%, trading on 6.84 million shares, to end the trade at $275.87. The stock changed hands in a range of $231.31 to $305.00, bringing its market capitalization to about $5.33 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $30.38 and was moved to the maximum level of $305.00. Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company’s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid.
Will ICPT Continue To Move Higher? Find Out Here
Galectin Therapeutics Inc. (NASDAQ:GALT) added 59.28%, to complete the trading session at $13.49, with a total volume of 7.08 million shares. The stock, on average, trades on a volume of 149,882 shares. It floated in a range of $8.75to $14.20 during the last trading session, with a beta value of 1.48. Its market capitalization now moved to about $155.10 million. In the past 52 weeks, the share price has not declined below $1.99 and above $14.20.
Why Should Investors Buy GALT After The Recent Gain? Just Go Here and Find Out
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) recorded a gain of 57.05% and was in a range of $6.29-$14.17 before closing at $9.80. The stock completed the day with a total volume of 3.64 million shares, versus an average volume of 101,613 shares. The share price hit its 52-week low of $5.76 and $14.17 was the best price. Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease.
What was the Moving Force behind CNAT on Bullish Run? Read This Research Report
Marina Biotech, Inc. (OTCMKTS:MRNA) added 52.17% yesterday, bringing its market capitalization around $11.46 million. The share price, after opening at $0.47, made a high of $0.90 and hovered above $0.43 to end the day at $0.700. The total number of shares that changed hands during the session was 1.42 million shares, as compared to average trading volume of 138,400 million shares. Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference (RNAi) and blocking messenger RNA (mRNA) translation.
For How Long MRNA will fight for Profitability? Read This Trend Analysis report
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)